Lactose (India)

Which are the latest news on Lactose (India)?

Why is Lactose (India) Ltd falling/rising?

As of 22-Jun, Lactose (India) Ltd's stock price is at 104.15, reflecting a decline of 0.76%. The stock has significantly underperformed the Sensex, with a 14.17% drop over the past month, despite increased investor participation.

As of 22-Jun, Lactose (India) Ltd's stock price is falling, currently at 104.15, which reflects a decrease of 0.8 or 0.76%. The stock has underperformed compared to the benchmark Sensex, which has gained 1.09% over the past week, while Lactose's stock has dropped by 4.45%. Over the last month, the stock has seen a significant decline of 14.17%, contrasting with the Sensex's increase of 2.23%. <BR><BR>Today, the stock has experienced a consecutive fall over the last two days, resulting in a total decline of 2.62% during this period. Additionally, while the stock is trading above its 100-day moving average, it is below its 5-day, 20-day, 50-day, and 200-day moving averages, indicating a short-term weakness in price momentum. <BR><BR>Despite a notable increase in investor participation, with delivery volume rising by 417.08% against the 5-day average, the overall performance today shows that Lactose (India) Ltd has underperformed its sector by 1.76%. This combination of factors contributes to the stock's current downward trend.

Should I buy, sell or hold Lactose (India) Ltd?

How big is Lactose (India)?

As of 10th June, Lactose (India) Ltd has a market capitalization of 134.00 Cr, with recent net sales of 163.30 Cr and a net profit of 6.07 Cr. Shareholder's funds are 58.74 Cr, and total assets amount to 133.47 Cr as of March 2025.

As of 10th June, Lactose (India) Ltd has a market capitalization of 134.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Lactose (India) reported Net Sales of 163.30 Cr and a Net Profit of 6.07 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 58.74 Cr and Total Assets totaling 133.47 Cr.

Who are in the management team of Lactose (India)?

The management team of Lactose (India) consists of Atul Maheshwari (Chairman & Managing Director), S M Maheshwari (Whole Time Director & CFO), and independent directors Pramod Kalani, G K Sarda, and Dhaval J Soni.

The management team of Lactose (India) includes the following individuals:<BR><BR>1. Atul Maheshwari - Chairman & Managing Director<BR>2. S M Maheshwari - Whole Time Director & CFO<BR>3. Pramod Kalani - Independent Non-Executive Director<BR>4. G K Sarda - Independent Non-Executive Director<BR>5. Dhaval J Soni - Independent Non-Executive Director<BR><BR>If you need more specific information about any of these individuals or their roles, feel free to ask!

Who are the peers of the Lactose (India)?

Lactose (India) peers include Krebs Biochem, Alpa Laboratorie, Bal Pharma, and others, with varying management risks and growth rates. Lactose (India) has a 1-year return of 7.60%, higher than Alpa Laboratorie but lower than Concord Drugs, which leads at 161.37%.

Peers: The peers of Lactose (India) are Krebs Biochem, Alpa Laboratorie, Bal Pharma, Smruthi Organic, Tyche Industries, Godavari Drugs, Concord Drugs, Balaxi Pharma, and Sotac Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Alpa Laboratorie and Balaxi Pharma, while Average management risk is found at Bal Pharma, Smruthi Organic, Tyche Industries, and Godavari Drugs, and the rest. Below Average management risk is noted for Lactose (India), Concord Drugs, and Sotac Pharma. In terms of Growth, Excellent growth is seen at Lactose (India), while Average growth is found at Sotac Pharma, and the rest have Below Average growth. For Capital Structure, Excellent capital structure is noted at Alpa Laboratorie and Balaxi Pharma, Good at Smruthi Organic, Average at Sotac Pharma, and Below Average for Lactose (India), Bal Pharma, Godavari Drugs, and Concord Drugs.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Concord Drugs at 161.37%, while the lowest is Alpa Laboratorie at -32.55%. Lactose (India) has a 1-year return of 7.60%, which is higher than Alpa Laboratorie but lower than Concord Drugs. Additionally, peers with a negative six-month return include Krebs Biochem, Alpa Laboratorie, and Lactose (India).

What does Lactose (India) do?

Lactose (India) Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology sector, specializing in the manufacturing and trading of edible and pharmaceutical grade lactose. As of March 2026, it reported net sales of 46 Cr and a net profit of 2 Cr, with a market cap of INR 134 Cr.

Overview: <BR>Lactose (India) Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology industry, engaged in the manufacturing and trading of pharmaceutical products, including edible and pharmaceutical grade lactose.<BR><BR>History: <BR>Lactose (India) Limited was incorporated in March 1991 as a Public Limited Company in Vadodara district of Gujarat. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>- Net Sales: 46 Cr (Quarterly Results - Mar 2026) <BR>- Net Profit: 2 Cr (Quarterly Results - Mar 2026) <BR>- Market Cap: INR 134 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>- P/E: 22.00 <BR>- Industry P/E: 34 <BR>- Dividend Yield: 0.00% <BR>- Debt Equity: 0.95 <BR>- Return on Equity: 9.37% <BR>- Price to Book: 2.07 <BR><BR>Contact Details: <BR>Address: Survey No 6, Village Poicha (Rania) Savli Vadodara Gujarat : 391780 <BR>Tel: 91-02667-244308/244729 <BR>Email: investor.lactose@gmail.com <BR>Website: http://www.lactoseindia.com

Are Lactose (India) Ltd latest results good or bad?

Lactose (India) Ltd's latest results show strong revenue growth of 64.82% and a net profit increase of 193.75%, indicating good demand. However, declining operating margins and weak return ratios raise concerns about long-term profitability and sustainability, making the overall outlook cautious.

Lactose (India) Ltd's latest results present a mixed picture. On one hand, the company reported a significant year-on-year revenue growth of 64.82% in Q4 FY26, reaching ₹45.77 crores, which is the highest topline figure in recent history. Additionally, the net profit surged to ₹1.88 crores, marking a remarkable increase of 193.75% compared to the same quarter last year. This growth indicates a strong demand for its products and a potential recovery in operational performance.<BR><BR>However, there are notable concerns. The operating margin of 10.99% reflects a decline from the previous year, indicating that while revenues are growing, profitability is under pressure due to rising input costs and operational inefficiencies. Furthermore, the company's return on equity (ROE) and return on capital employed (ROCE) remain weak, suggesting challenges in capital efficiency and overall profitability.<BR><BR>The stock has seen a recent surge, with a 20.92% increase over the past week, but this short-term momentum may not fully offset the underlying structural weaknesses, such as elevated leverage and a concerning promoter pledge of 26.07% of shares.<BR><BR>In summary, while the latest results show impressive revenue and profit growth, the persistent operational challenges and weak return ratios indicate that the overall investment case remains cautious. Therefore, the results can be seen as good in terms of growth but bad when considering the long-term sustainability and profitability of the business.

When is the next results date for Lactose (India) Ltd?

The next results date for Lactose (India) Ltd is 13 February 2026.

The next results date for Lactose (India) Ltd is scheduled for 13 February 2026.

How has been the historical performance of Lactose (India)?

Lactose (India) has experienced significant growth, with net sales increasing from INR 34.96 crore in March 2021 to INR 116.40 crore in March 2025, and profit before tax improving from a loss of INR 3.27 crore to a profit of INR 6.92 crore in the same period. Total liabilities rose to INR 133.47 crore, while cash flow from operating activities showed a positive inflow of INR 2.00 crore in March 2025.

Answer:<BR>The historical performance of Lactose (India) shows a significant growth trajectory in net sales and profitability over the years, with net sales increasing from INR 34.96 crore in March 2021 to INR 116.40 crore in March 2025. The total operating income has mirrored this growth, reaching INR 116.40 crore in March 2025, up from INR 34.96 crore in March 2021. The operating profit (PBDIT) has also seen fluctuations, peaking at INR 20.13 crore in March 2024 before slightly declining to INR 18.41 crore in March 2025. Profit before tax has improved from a loss of INR 3.27 crore in March 2021 to a profit of INR 6.92 crore in March 2025, while profit after tax followed a similar trend, rising from a loss of INR 2.48 crore in March 2021 to INR 5.16 crore in March 2025. <BR><BR>In terms of expenses, raw material costs have increased significantly, reaching INR 60.51 crore in March 2025, which reflects the rising operational scale. The company’s total liabilities have grown from INR 84.00 crore in March 2020 to INR 133.47 crore in March 2025, indicating increased borrowing, particularly in short-term borrowings, which rose to INR 30.31 crore in March 2025. Total assets have also increased, reaching INR 133.47 crore in March 2025, supported by a rise in current assets, particularly inventories and sundry debtors. Cash flow from operating activities has remained stable, with a notable cash inflow of INR 2.00 crore in March 2025, compared to a net outflow in previous years. Overall, Lactose (India) has demonstrated resilience and growth in its financial performance over the past several years.<BR><BR>Breakdown:<BR>Lactose (India) has shown a robust growth pattern in its financial metrics over the years. Net sales surged from INR 34.96 crore in March 2021 to INR 116.40 crore in March 2025, reflecting a strong upward trend. Total operating income followed suit, reaching INR 116.40 crore in March 2025. Operating profit (PBDIT) peaked at INR 20.13 crore in March 2024 but slightly declined to INR 18.41 crore in March 2025. Profit before tax improved significantly from a loss of INR 3.27 crore in March 2021 to a profit of INR 6.92 crore in March 2025, while profit after tax rose from a loss of INR 2.48 crore in March 2021 to INR 5.16 crore in March 2025. The company’s total liabilities increased to INR 133.47 crore in March 2025, driven by higher short-term borrowings, while total assets also grew to INR 133.47 crore, supported by rising inventories and sundry debtors. Cash flow from operating activities remained stable, with a net cash inflow of INR 2.00 crore in March 2025, indicating improved liquidity and operational efficiency.

Who are the top shareholders of the Lactose (India)?

The top shareholders of Lactose (India) include Sangita Maheshwari, who holds 30.73%, and Madhusha Holdings Private Limited, the largest public shareholder at 3.97%. Individual investors collectively own 38.31%, with no mutual funds or foreign institutional investors currently involved.

The top shareholders of Lactose (India) include the promoters, who hold a significant majority of the shares. The promoter with the highest holding is Sangita Maheshwari, owning 30.73% of the company. Additionally, Madhusha Holdings Private Limited is the highest public shareholder, holding 3.97%. Individual investors collectively hold 38.31% of the shares, while there are currently no mutual funds or foreign institutional investors (FIIs) involved in the company.

Is Lactose (India) overvalued or undervalued?

As of March 17, 2025, Lactose (India) is considered undervalued with a PE ratio of 25.80 and strong financial metrics, despite a year-to-date stock return of -54.84%, making it an attractive investment compared to peers like Sun Pharma and Cipla.

As of 17 March 2025, Lactose (India) has moved from a fair to an attractive valuation grade, indicating a shift in market perception. The company is currently considered undervalued, supported by a PE ratio of 25.80, an EV to EBITDA of 10.37, and a ROCE of 18.05%. In comparison to its peers, Lactose's valuation metrics stand out; for instance, Sun Pharma has a significantly higher PE ratio of 35.25, while Cipla, another attractive peer, has a PE of 22.99.<BR><BR>Despite recent underperformance, with a year-to-date stock return of -54.84% compared to the Sensex's 5.58%, Lactose (India) presents a compelling investment opportunity given its favorable ratios and the attractive valuation relative to peers like Dr. Reddy's Labs (PE of 19.49) and Zydus Lifesciences (PE of 20.61). This suggests that the market may not fully appreciate Lactose's potential, reinforcing the conclusion that it is undervalued.

What is the technical trend for Lactose (India)?

As of May 26, 2025, Lactose (India) shows a mildly bearish technical trend, with bearish signals from Bollinger Bands and moving averages, despite some mildly bullish indicators in the weekly MACD and KST.

As of 26 May 2025, the technical trend for Lactose (India) has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD shows a mildly bearish trend. The Bollinger Bands are bearish on both weekly and monthly time frames, and daily moving averages are also bearish. The KST presents a mildly bullish signal on the weekly chart but is mildly bearish on the monthly. Dow Theory reflects a mildly bearish outlook on the weekly and a bullish stance on the monthly. Overall, the current technical stance is mildly bearish, influenced by the bearish signals from Bollinger Bands and moving averages, despite some mildly bullish indicators in the MACD and KST on the weekly time frame.

Has Lactose (India) declared dividend?

No Dividend History Available